MELINTA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-35405
(Commission
File Number)

45-4440364
(I.R.S. Employer
Identification No.)

300 George Street, Suite 301, New Haven, CT
(Address of principal executive offices)

06511
(Zip Code)

Registrant's telephone number, including area code (312) 767-0291

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.

On March 13, 2018, Melinta Therapeutics, Inc. (the “Company”) issued a press release announcing its results for its fourth quarter and fiscal year ended December 31, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

Item 7.01. Regulation FD Disclosure.

On March 13, 2018, in connection with the Company’s quarterly earnings call, the Company made available the investor presentation furnished herewith as Exhibit 99.2 to this Current Report on Form 8-K on the Company’s investor website, ir.melinta.com.

The information in this Item 7.01 (including Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing. The information contained in, or that can be accessed through the Company’s website, is not a part of this filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<table>
<thead>
<tr>
<th>Exhibit No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>99.1</td>
<td>Press Release titled “Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results,” dated March 13, 2018</td>
</tr>
<tr>
<td>99.2</td>
<td>Investor presentation, dated March 13, 2018</td>
</tr>
</tbody>
</table>
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Melinta Therapeutics, Inc.

By: /s/ Paul Estrem
   Paul Estrem
   Chief Financial Officer

Dated: March 13, 2018
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

**Baxdela™ (delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI**

**Acquired Infectious Disease Business from The Medicines Company on January 5, 2018**

**First Earnings Report as a Public Company**

NEW HAVEN, Conn., March 13, 2018 – Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today reported financial results and provided an update on commercial and regulatory activities for the quarter ended December 31, 2017. During the quarter, the Company completed its reverse merger with Cempra, Inc. (Cempra) to become a publicly traded company. Fourth quarter and full year 2017 results include the addition of the Cempra business as of the merger date of November 3, 2017. Immediately following the quarter, the Company acquired the infectious disease business of The Medicines Company, including products Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection. This press release includes highlights from The Medicines Company infectious disease business as of acquisition close on January 5, 2018.

“Following Melinta becoming a public company on November 3, we swiftly acquired the infectious disease business from The Medicines Company, transforming Melinta into the largest global, pure-play antibiotics company. Today, we have a strong portfolio of products including Vabomere, Orbactiv and Minocin for Injection, together with our first drug Baxdela that we launched just this quarter,” said Dan Wechsler, president and CEO of Melinta.

“We have a strong combined team, including the addition of over 150 seasoned professionals at the time of The Medicines Company transaction, and a leading pipeline of development and discovery assets including those from our own Nobel Prize-winning discovery platform. 2018 will be an exciting year for Melinta, and we look forward to launching our products, furthering our pipeline and telling our story focused on bringing life-saving anti-infective products to areas of unmet need and, in turn, building strong shareholder value over the long-term,” Mr. Wechsler concluded.

**Full Year 2017 and Recent Business Highlights**

- March 2, 2017 - entered into commercial and co-development agreement with Menarini Group for delafloxacin in 68 countries outside of the United States
  - >$100 million of upfront and potential milestone payments and double-digit royalties on sales in partnered territories
  - Menarini pays 50% of future delafloxacin indication-expansion efforts
• June 19, 2017 - the U.S. Food and Drug Administration (FDA) approved Baxdela indicated in adults for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria
  • A fluoroquinolone that exhibits activity against both Gram-positive and Gram-negative pathogens, including the distinction of being the only approved drug in its class that covers methicillin-resistant Staphylococcus aureus (MRSA)
  • A fixed-dose therapy with limited disease or drug interactions and is available in interchangeable intravenous and oral formulations
• September 26, 2017 - announced the expansion of agreement with Eurofarma Laboratorios S.A. (Eurofarma) to include 19 countries in South and Central America and the Caribbean
  • Eurofarma has submitted a marketing authorization for delafloxacin in Argentina
• November 3, 2017 - completed the reverse merger with Cempra to become a publicly traded company
• January 5, 2018 - acquired the infectious disease business of The Medicines Company, including approved products Vabomere, Orbactiv and Minocin for Injection
  • Added a well-experienced commercial, medical affairs and commercial support organization
  • Integration nearing completion
  • Minimal disruption to product launches or performance, including Vabomere, which was recently launched
• February 6, 2018 - launched Baxdela in the United States
• March 8, 2018 - partner Menarini submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for delafloxacin for treatment of adults with ABSSSI

**Q4 and Full Year 2017 Financial Results**

Melinta reported a net loss available to shareholders of $20.9 million, or $1.48 per share, for the quarter ended December 31, 2017 compared to a net loss of $27.7 million for the same period in 2016. For the full year ended December 31, 2017, the Company reported net loss available to shareholders of $78.2 million.

Research and development expenses were $11.6 million for the quarter ended December 31, 2017, compared to $16.3 million for the same period in 2016. The decrease was driven primarily by fourth quarter 2016 New Drug Application (NDA)-related fees and milestone payments and lower manufacturing costs. For the full year ended December 31, 2017, the Company reported R&D expenses of $49.5 million.
Selling, general and administrative expenses were $37.3 million for the quarter ended December 31, 2017, compared to $4.6 million for the same period in 2016. The increase was driven primarily by commercial launch preparation activities for Baxdela and transaction- and integration-related costs, including severance and stock-based compensation, due to the merger. For the full year ended December 31, 2017, the Company reported selling, general and administrative expenses of $63.3 million.

As of December 31, 2017, Melinta had cash and cash equivalents of $128.4 million. In addition, the Company has available debt capacity under the Deerfield agreement. It is anticipated that Melinta may strengthen its cash position through the completion of business development activities, similar to the transaction completed with Menarini. The Company also recently filed a universal shelf registration statement on Form S-3 with the SEC, which will allow the Company to provide more timely and efficient access to the capital markets should the Company decide to issue securities in the future, subject to market conditions.

2017 and Recent Pipeline and Publication Highlights
Includes highlights from The Medicines Company infectious disease business as of acquisition close on January 5, 2018.

- Publication of Baxdela Outcomes in ABSSSI Patients with Fluoroquinolone-resistant S. aureus Isolates
- Presented Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek 2017
- Announced Topical Radezolid (partnered product) Well Tolerated in Phase 1 Study for Treatment of Acne, Initiation of Program in Patients with Bacterial Vaginosis, and Qualified Infectious Disease Product (QIDP) Designation for Bacterial Vaginosis
- Publication in *Journal of Antimicrobial Chemotherapy* of 1st Pivotal Phase 3 Baxdela Trial Data in ABSSSI
- Complete Results from the Phase 3 TANGO-1 Data for Vabomere Published in *The Journal of the American Medical Association (JAMA)*
- 2nd Pivotal Phase 3 Baxdela ABSSSI Trial Data Published in *Clinical Infectious Diseases*
- Discovery Platform Oral Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and American Society for Microbiology (ASM Microbe) Highlighting Progress Towards Leads for Drug-resistant *Neisseria gonorrhoeae* and Multidrug- and Extremely Drug-resistant ESKAPE Pathogens
2018 Upcoming Potential Catalysts

• Pivotal Phase 3 data for Baxdela in community-acquired bacterial pneumonia (CABP)
• Vabomere EMA regulatory approval decision
• TANGO-2 additional data and potential publications
• Additional ex-US approvals for Baxdela in Central and South America
• Ex-US partnership opportunities for Vabomere, Orbactiv and Minocin for Injection
• IND-enabling studies for lead ESKAPE compound

Conference Call and Webcast

Melinta’s earnings conference call for the quarter ended December 31, 2017 will be broadcast at 8:30am EDT on March 13, 2018. The live webcast can be accessed under “Events and Presentations” in the Investor Relations section of Melinta’s website at www.melinta.com.

Investors wishing to participate in the call should dial: 877-377-7553 and international investors should dial: 253-237-1151. The conference ID is 7787858. Investors can also access the call at http://ir.melinta.com/events/event-details/melinta-therapeutics-q4-2017-earnings-call.

A live webcast of the call will be available online from the investor relations section of the company website at www.melinta.com and will be archived there for 30 days. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 7787858.

About Melinta Therapeutics

Melinta Therapeutics, Inc. is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin); Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Visit www.melinta.com for more information.
About Baxdela (delafloxacin)

For more information about Baxdela, including the Medication Guide and important safety information, including the Boxed Warning, see www.baxdela.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this communication constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.

Risks and uncertainties for Melinta include, but are not limited to: the fact that we have incurred significant operating losses since inception and will incur continued losses for the foreseeable future; our limited operating history; our need for future capital; uncertainties of cash flows and inability to meet working capital needs as well as other milestone, royalty and payment obligations; the fact that our independent registered public accounting firm’s report on the Company’s 2016 and 2017 financial statements contains an explanatory paragraph that states that our recurring losses from operations and our need to obtain additional capital raises substantial doubt about our ability to continue as a going concern; our substantial indebtedness; risks related to our commercial launches of our products and our inexperience as a company in marketing drug products; the degree of market acceptance of our products among physicians, patients, health care payors and the medical community; the pricing we are able to achieve for our products; failure to obtain and sustain an adequate level of reimbursement for our products by third-party payors; inaccuracies in our estimates of the market for and commercialization potential of our products; failure to maintain optimal inventory levels to meet commercial demand for any of our products; risks that our competitors are able to develop and market products that are preferred over our products; risks that our competitors are able to develop and market products that are preferred over our products; our dependence upon third parties for the manufacture and supply of our marketed products; failure to achieve the benefits of our recently completed transactions with Cempra and The Medicines Company; failure to establish and maintain development and commercialization collaborations; uncertainty in the outcome or timing of clinical trials and/or receipt of regulatory approvals for our product candidates; undesirable side effects of our products; failure of third parties to conduct clinical trials in accordance with their contractual obligations; our
ability to identify, develop, acquire or in-license products; difficulties in managing the growth of our company; the effects of recent comprehensive tax reform; risks related to failure to comply with extensive laws and regulations; product liability risks related to our products; failure to retain key personnel; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; risks relating to third party infringement of intellectual property rights; our ability to maintain effective internal control over financial reporting; unfavorable outcomes in any of the class action and shareholder derivative lawsuits currently pending against the Company; and the fact that a substantial amount of shares of common stock may be sold into the public markets by one or more of our large shareholders in the near future. Many of these factors that will determine actual results are beyond Melinta’s ability to control or predict.

Other risks and uncertainties are more fully described in our Annual Report on Form 10-K for the year ended December 31, 2017, which we expect to file promptly with the SEC, and in other filings that Melinta makes and will make with the SEC. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in this press release speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date after the date stated herein.

<table>
<thead>
<tr>
<th>Assets</th>
<th>December 31, 2017 (in 000s)</th>
<th>December 31, 2016 (in 000s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$128,387</td>
<td>$11,409</td>
</tr>
<tr>
<td>Receivables</td>
<td>7,564</td>
<td>454</td>
</tr>
<tr>
<td>Inventory</td>
<td>10,825</td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>2,988</td>
<td>3,226</td>
</tr>
<tr>
<td>Total current assets</td>
<td>149,764</td>
<td>15,089</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>1,596</td>
<td>1,101</td>
</tr>
<tr>
<td>Intangible assets</td>
<td>7,500</td>
<td></td>
</tr>
<tr>
<td>Other assets</td>
<td>1,413</td>
<td>444</td>
</tr>
<tr>
<td>Total assets</td>
<td>$160,273</td>
<td>$16,634</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities and Stockholders’ Equity</th>
<th>December 31, 2017 (in 000s)</th>
<th>December 31, 2016 (in 000s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$31,446</td>
<td>$11,496</td>
</tr>
<tr>
<td>Notes payable, net</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other current liabilities</td>
<td>284</td>
<td>848</td>
</tr>
<tr>
<td>Total current liabilities</td>
<td>31,730</td>
<td>23,419</td>
</tr>
<tr>
<td>Notes payable, net of current and debt discount</td>
<td>39,555</td>
<td>12,647</td>
</tr>
<tr>
<td>Convertible promissory notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>10,008</td>
<td>9,008</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>6,644</td>
<td>1,541</td>
</tr>
<tr>
<td>Total liabilities</td>
<td>87,937</td>
<td>91,742</td>
</tr>
<tr>
<td>Convertible preferred stock</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stockholders’ equity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common stock</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Additional paid in capital</td>
<td>644,973</td>
<td>220,292</td>
</tr>
<tr>
<td>Accumulated deficit</td>
<td>(572,659)</td>
<td>(513,743)</td>
</tr>
<tr>
<td>Total stockholders’ equity</td>
<td>72,336</td>
<td>(293,451)</td>
</tr>
<tr>
<td>Total liabilities and stockholders’ equity</td>
<td>$160,273</td>
<td>$16,634</td>
</tr>
<tr>
<td></td>
<td>Three Months Ended December 31, 2017 (in 000s)</td>
<td>Twelve Months Ended December 31, 2017 (in 000s)</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contract revenue</td>
<td>$4,231</td>
<td>$13,959</td>
</tr>
<tr>
<td>License</td>
<td>$—</td>
<td>$19,905</td>
</tr>
<tr>
<td>Total revenue</td>
<td>4,231</td>
<td>33,864</td>
</tr>
<tr>
<td><strong>Operating expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research and development</td>
<td>$11,599</td>
<td>$49,475</td>
</tr>
<tr>
<td>Selling, general and administrative</td>
<td>$37,349</td>
<td>$63,325</td>
</tr>
<tr>
<td>Total operating expenses</td>
<td>48,948</td>
<td>112,800</td>
</tr>
<tr>
<td>Loss from operations</td>
<td>$(44,717)</td>
<td>$(78,936)</td>
</tr>
<tr>
<td><strong>Other income (expense), net</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest income</td>
<td>130</td>
<td>155</td>
</tr>
<tr>
<td>Interest expense</td>
<td>$(1,859)</td>
<td>$(7,624)</td>
</tr>
<tr>
<td>Change in fair value of tranche assets and liabilities</td>
<td>—</td>
<td>$(1,313)</td>
</tr>
<tr>
<td>Change in fair value of warrant liability</td>
<td>—</td>
<td>335</td>
</tr>
<tr>
<td>Loss on extinguishment of debt</td>
<td>—</td>
<td>$(607)</td>
</tr>
<tr>
<td>Other income</td>
<td>3</td>
<td>98</td>
</tr>
<tr>
<td>Bargain purchase gain</td>
<td>27,663</td>
<td>27,663</td>
</tr>
<tr>
<td>Total other income (expense), net</td>
<td>25,937</td>
<td>$(4,731)</td>
</tr>
<tr>
<td><strong>Net loss</strong></td>
<td>$(18,780)</td>
<td>$(58,916)</td>
</tr>
<tr>
<td>Accretion of convertible preferred stock dividends</td>
<td>$(2,098)</td>
<td>$(19,259)</td>
</tr>
<tr>
<td><strong>Net loss available to common shareholders</strong></td>
<td>$(20,878)</td>
<td>$(73,932)</td>
</tr>
<tr>
<td>Basic and diluted net loss per share</td>
<td>$(1.48)</td>
<td>$(21.86)</td>
</tr>
<tr>
<td>Basic and diluted weighted-average shares outstanding</td>
<td>14,105</td>
<td>3,577</td>
</tr>
</tbody>
</table>

For More Information:

**Media Inquiries:**
Amra Maynard
(917) 302-2702
Amra.maynard@inventivhealth.com

**Investor Inquiries:**
Lisa DeFrancesco
(847) 681-3217
ldefrancesco@melinta.com
Raj Mistry
(312) 801-2051
rmistry@melinta.com
Melinta Therapeutics
*The Antibiotics Company*

Q4 2017 Earnings Conference Call
March 13, 2018
Cautionary Note Regarding Forward-looking Statements

- This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

- You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.

- Risks and uncertainties for Melinta Therapeutics, Inc. (the “Company”) are more fully described in the Company’s filings with the SEC, including in its Annual Report on Form 10-K for the year ended December 31, 2017, which the Company expects to file promptly with the SEC and, its Quarterly Reports on Form 10-Q.
1. Business Overview
Dan Wechsler, President and CEO
   – Q4 2017 Highlights and Recent Events
   – Integration Update
   – Commercial Overview
   – Pipeline and Publication Highlights

2. Financial Results and Outlook
Paul Estrem, CFO

3. Conclusion and 2018 Catalysts
Dan Wechsler, President and CEO
Q4 Highlights and Recent Events

Business
- Merged with Cempra to become a publicly-traded company
- Acquired The Medicines Company ID Business including three approved products and strong ID-focused organization
- Integration nearing completion with strong, combined team

Product
- Vabomere launched Oct. 28, 2017
- Baxdela launched Feb. 6, 2018
- Baxdela ABSSSI EMA regulatory filing submitted by partner Menarini
- Ex-US MA filed for Baxdela in Argentina with partner Eurofarma
- Discovery asset Radezolid
  - Entered Phase 2 for acne vulgaris
  - Received FDA QIDP designation for bacterial vaginosis

Transformed into Largest Pure-play Antibiotics Company
>$1 Billion US Peak Sales Potential From 4 Approved Products
Integration Nearing Completion

- Strong, experienced, combined team executing on product launches, assessing pipeline and developing New Melinta culture
- Products performing during period of transition
  - Vabomere and Baxdela launches underway with early favorable trends
  - Minocin and Orbactiv combined experiencing double-digit growth
- Pharmaceutical Development Committee established to evaluate pipeline priorities
- All key milestones & deadlines met during period of integration
Robust and Complementary Product Portfolio of Four Approved Assets with Significant Commercial Potential

<table>
<thead>
<tr>
<th>Baxdela™</th>
<th>VABOMERE™</th>
</tr>
</thead>
<tbody>
<tr>
<td>(delafloxacin)</td>
<td>meropenem and vaborbactam</td>
</tr>
<tr>
<td>450 mg tablets</td>
<td>for injection (4 g)</td>
</tr>
<tr>
<td>300 mg vial for injection</td>
<td></td>
</tr>
<tr>
<td>ABSSSI Patients with Comorbidities in the Hospital, Emergency and Outpatient Setting</td>
<td>cUTI including KPC-mediated CRE</td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th>Orbactiv®</th>
<th>Minocin®</th>
</tr>
</thead>
<tbody>
<tr>
<td>(oritavancin)</td>
<td>(minocycline)</td>
</tr>
<tr>
<td>for injection</td>
<td>for injection</td>
</tr>
<tr>
<td>Gram (+) ABSSSI in the Emergency and Outpatient Setting</td>
<td>Acinetobacter in the Hospital Setting</td>
</tr>
</tbody>
</table>

Unique Market Value for Each Approved Product Optimized By Company Infrastructure and Commitment to Antibiotics
Industry Leading Organization with Deep Expertise

- Strong Operating Infrastructure
- 4 Approved Brands
- 18 Medical Science Liaisons
- 300+ Employees
- 17 Years Average Sales Experience
- 135+ Key Account Manager Territories

(Infectious Disease Business)
# Experienced Combined Management Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Experience/Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dan Wechsler</td>
<td>CEO</td>
<td>&gt;25 years; led Zyvox at Pharmacia; led pharma, generics and OTC at Bausch &amp; Lomb; CEO at Smile Brands</td>
</tr>
<tr>
<td>Paul Estrem</td>
<td>CFO</td>
<td>&gt;25 years; CFO of multiple business units at Baxter</td>
</tr>
<tr>
<td>Sue Cammarata, M.D.</td>
<td>CMO</td>
<td>&gt;20 years; development of Cubicin and Zyvox</td>
</tr>
<tr>
<td>Erin Duffy, Ph.D.</td>
<td>CSO</td>
<td>&gt;20 years; leading expert in structure &amp; function of bacterial ribosome</td>
</tr>
<tr>
<td>Juliet Agranoff</td>
<td>SVP, HR</td>
<td>&gt;20 years; head of HR for The Medicines Company ID franchise</td>
</tr>
<tr>
<td>Lisa DeFrancesco</td>
<td>SVP, IR</td>
<td>&gt;15 years; VP investor relations at Allergan</td>
</tr>
<tr>
<td>Peter Di Roma</td>
<td>SVP, QA/RA</td>
<td>&gt;20 years; regulatory approval of Zyvox and Baxdela</td>
</tr>
<tr>
<td>Michael McGuire</td>
<td>SVP, Comm'l</td>
<td>&gt;25 years of pharma marketing and anti-infectives</td>
</tr>
<tr>
<td>Kevin Conway</td>
<td>VP, Tech Ops</td>
<td>&gt;30 years; operational management of Humira and Kaletra launches</td>
</tr>
<tr>
<td>Kate Farrington</td>
<td>VP, Compliance</td>
<td>&gt;20 years of pharma industry compliance/office roles</td>
</tr>
</tbody>
</table>
Organization Dedicated to Antibiotic Stewardship

Antibiotic

Stewardship

Right Patient, Right Product, Right Length of Time
### Commercial Overview

<table>
<thead>
<tr>
<th>Product</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Baxdela**<br>(delafloxacin) | - Launched February 6, 2018  
- Favorable early uptake |
| **VABOMERE**<br>(meropenem and vaborbactam for injection [4g]) | - Launched October 28, 2017  
- Formulary approvals and uptake trends positive  
- 50% of high priority target accounts have access |
| **Orbactiv**<br>(oritavancin) | - Q4 2017 strongest quarter since 2014 launch  
  - Experienced double-digit growth |
| **Minocin**<br>(minocycline) | - Renewed focus supports continued sales growth  
- Complementary product offering to Vabomere |
Vabomere: Fixed Dose, IV Monotherapy Targeting KPC-producing, Carbapenem-resistant Enterobacteriaceae

Indications:
• cUTI (approved)
• Acute pyelonephritis (approved)

Attributes / Differentiation:
• Product for serious Gram-negative pathogens, an area of significant need
• Fixed dose, no requirement for plasma monitoring
• Meropenem “backbone” with safety profile similar to meropenem alone
• Conducted first & only supportive study as monotherapy in CRE infections versus a range of “best available therapy” regimens

- $990/day WAC
- 2g meropenem / 2g vaborbactam
- TID dosing
- Fixed dose
Vabomere Reporting Positive Initial Adoption Trends

- >150 Accounts with Product Available
- >150 Accounts with Upcoming P&T or Sub-committee Review
- 50% Accounts Already Placed Re-orders
- 100% of Susceptibility Testing Devices* Currently Available

* Semi-automated testing devices
Baxdela: Fixed Dose, IV/Oral Monotherapy Targeting Serious Mixed Pathogen Infections

Indications:
• ABSSSI (approved)
• CABP (single Phase 3, >75% enrolled)

Attributes / Differentiation:
• Gram-positive, Gram-negative, MRSA (only approved FQ with coverage)
• Interchangeable IV and Oral administration
• Fixed dose, no food effect, no drug interactions (other than antacids)
• <1% discontinuation due to treatment-related AEs in ABSSSI Phase 3s
• Large database of co-morbid patients studied

- $135/day WAC
- 450mg tablet
- BID dosing
- Fixed dose

- $265/day WAC
- 300mg vial
- BID dosing
- Fixed dose
Large ABSSSI Market Opportunity for Baxdela in Hospital, Emergency and Selected Outpatient Areas

- 10 Million Community Cases
- 2 Million Emergency Department Cases
- 3 Million Hospitalized Cases
- Selected Outpatient, i.e. Peri- and Post-acute Care

Melinta
Therapeutics
First Month of Baxdela Commercial Indicators Promising

- **>50M**: Commercial Lives Have Product Access (Tier 3, No Prior Authorization)
- **71**: Accounts Allowing Product Access
- **34**: Hospital Formulary Reviews Scheduled in Next Quarter
- **100%**: of Susceptibility Testing Devices* Currently Available

* Semi-automated testing devices
Orbactiv & Minocin Strategy
Demonstrating Consistent Growth Since Launch

1. Drive Value from Reinvigorated Salesforce
2. Leverage Power of 100% Dedicated Anti-infectives Business
3. Focus on Newly Accessible Opportunities, e.g. Outpatient Clinics Surrounding Hospitals

$34 Million FY 2017 Sales; Anticipate Steady Growth
Attractive Product Portfolio for Multiple Sites of Care

Hospital Avoidance

Hospital

Transition of Care (Post-Discharge)

Specialty Outpatient

Baxdela®
(delaflouxacin)

Orbactiv®
(orravancin)
for injection

Baxdela®
(delaflouxacin)

Orbactiv®
(orravancin)
for injection

Baxdela®
(delaflouxacin)

Orbactiv®
(orravancin)
for injection

Baxdela®
(delaflouxacin)

Orbactiv®
(orravancin)
for injection

VABOMERE™
(reserpren and tigecycline)
for injection

Minocin®
(minocycline)
for injection

Melinta
Therapeutics
Company Pipeline Update

- EU partner Menarini submitted EMA regulatory submission for ABSSSI: Q1 2018
- LATAM partner Eurofarma submitted MA for Argentina for ABSSSI: Q1 2018
- Phase 3 CABP enrollment completion: Expected Q4 2018
- EMA regulatory approval: Expected Q4 2018
- TANGO-1 published; TANGO-2 data available
- IV reformulation under evaluation
- EMA approval pathway under evaluation
- Phase 2 Bone & Joint study: 6 month primary endpoint data
- ABSSSI Phase 3 met primary endpoint
- Continuing to evaluate options
- Meeting scheduled with BARDA
- Japan partner Toyama completed enrollment in four studies
- Phase 2 topical acne vulgaris trial ongoing
- Formulation development initiated for bacterial vaginosis, received QIDP
- Evaluating efficacy and safety credentials of >100 compounds that focus on multiple target product profiles in anticipation of IND-enabling studies in 2018
Financial Results & Guidance

Paul Estrem, Chief Financial Officer
## Financial Highlights

<table>
<thead>
<tr>
<th>Metrics (in millions)</th>
<th>12/31/2017</th>
<th>01/05/2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full Year Revenue*</td>
<td>$33.9</td>
<td>N.A.</td>
</tr>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$128.4</td>
<td>N.A.</td>
</tr>
<tr>
<td>Long-term Debt</td>
<td>$40.0</td>
<td>$148.0</td>
</tr>
<tr>
<td>Common Shares Outstanding</td>
<td>22.0</td>
<td>31.3</td>
</tr>
<tr>
<td>Options, RSUs and Warrants Outstanding</td>
<td>2.4</td>
<td>6.2</td>
</tr>
</tbody>
</table>

### 2018 Cash Supports Execution of Near-term Strategic Objectives

* Includes one-time license revenue of $19.9 million
2018 Key Financial Items

Revenue
- Vabomere and Baxdela in early launch phase
- Continued combined growth of Orbactiv and Minocin (full year 2017 generated $34 million)
- Cost reimbursement and milestone achievements from collaborations and partnerships

Key Financial Items
- Operating expenses (R&D and SG&A): $175-$200 million
- Interest expense: $18 million

Opportunity to Achieve Cash Flow Positive During 2020
Closing and Catalysts

Dan Wechsler, President & Chief Executive Officer
Melinta Therapeutics, The Antibiotics Company

- **Products**: Four approved antibiotic assets with >$1 billion sales potential; 4 marketed products incl. 2 launches underway
- **Pipeline**: Robust drug development pipeline to fuel future growth; Global footprint* with significant expansion potential
- **Operational Strength**: Strong combined experienced talent, processes and capabilities
- **Discovery**: Nobel Prize-winning technology; Proprietary discovery know-how to address emerging resistance

**Attractive Growth Equity Story; Robust Antibiotics Pipeline from Discovery to Commercial; World-class Capabilities**

* Including partnership agreements
# 2018 Key Catalysts

<table>
<thead>
<tr>
<th>Category</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baxdela</td>
<td>- Launch updates&lt;br&gt;- Phase 3 CABP study enrollment completion&lt;br&gt;- Country approvals in South &amp; Central America</td>
</tr>
<tr>
<td>Vabomere</td>
<td>- Launch updates&lt;br&gt;- EMA regulatory approval&lt;br&gt;- TANGO-2 additional data and potential publications</td>
</tr>
<tr>
<td>Other</td>
<td>- Ex-US partnerships for balance of portfolio&lt;br&gt;- Business development opportunities&lt;br&gt;- Progress on ESKAPE program&lt;br&gt;- Focused publication strategy; 30+ planned</td>
</tr>
</tbody>
</table>

*When Strategy is Clear, EXECUTION Becomes the Strategy*